🟢 Outlook Therapeutics is trading 19% up today as buyers return following a sharp post-FDA approval selloff

Outlook Therapeutics is trading 19% up at $1.08 as buyers step back in following a sharp post-FDA approval selloff in its wet AMD therapy, LYTENAVA.

• The rebound is driven by bargain hunting and portfolio rebalancing after heavy profit-taking occurred immediately following the regulatory approval.
• The stock's recovery comes despite general weakness among biotechnology peers and a cautious broader market sentiment ahead of the Federal Reserve's interest rate decision.